
News|Articles|January 1, 2004
Docetaxel/platinum combinations are efficacious in treatment of NSCLC
A regimen of docetaxel and cisplatin offers better survival and response rates than a combination of vinorelbine and cisplatin in the treatment of advanced non-small-cell lung cancer, according to a phase 3 study published in the online version of the Journal of Clinical Oncology. In addition, the findings demonstrated that docetaxel is as effective as vinorelbine/cisplatin when combined with another platinum, carboplatin.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The Rise of AI in Healthcare Shows Both Progress and Roadblocks
2
Researchers Urge Payers to Encourage, not Inhibit, Biosimilar Competition
3
Challenges & Solutions behind post-acute care models with OneHome's Noel Gilliam
4
Izervay Continued to Show Benefit in Geographic Atrophy in Open-Label Study
5



















































